Ani Pharmaceuticals (ANIP) EPS (Diluted) Growth (3y) (2014 - 2026)
Ani Pharmaceuticals (ANIP) EPS (Diluted) Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | 15.17% |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | 3.25% |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | 2.66% |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 11.56% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -35.09% |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 13.29% |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | 36.48% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Ani Pharmaceuticals | 1.63 Bn | 1.27 Bn | 165.89 Mn | 51.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 51.05% |
| Mar 31, 2026 | 179.81% |
| Dec 31, 2025 | 86.90% |
| Sep 30, 2025 | 62.04% |
| Jun 30, 2025 | 34.36% |
| Mar 31, 2025 | 37.49% |
| Dec 31, 2024 | 34.09% |
| Sep 30, 2024 | -51.07% |
| Jun 30, 2024 | 50.75% |
| Mar 31, 2024 | 414.23% |
| Dec 31, 2023 | 28.78% |
| Sep 30, 2023 | 134.67% |
| Jun 30, 2023 | 32.30% |
| Mar 31, 2023 | 28.18% |
| Dec 31, 2022 | 10.70% |
| Sep 30, 2022 | -54.86% |
| Jun 30, 2022 | -55.55% |
| Mar 31, 2022 | -228.68% |
| Dec 31, 2021 | -83.58% |
| Sep 30, 2021 | -41.96% |